---
document_datetime: 2025-06-11 11:16:41
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sugammadex-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sugammadex-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.1509362
conversion_datetime: 2025-12-22 20:26:59.307167
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sugammadex Mylan

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 27/05/2025                          | 06/06/2025                                  | SmPC and PL                      | To extend the indication to include treatment of |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000267163                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To extend the indication to include treatment of pediatric patients from birth to less than 2 years. The sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated in consequence. The PL is updated accordingly. The change follows assessment of the same change to the reference product, Bridion. In addition, the MAH took the opportunity to update the PI to align with the QRD template, and to update the information for the local representative in CY. Furthermore, the MAH took the opportunity to implement editorial changes to the PI in BG, DE, FI, HR, HU, IT, NL, NO Ro and SL to align with the reference product PI and the   |            |     | pediatric patients from birth to less than 2 years. The sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated in consequence. The PL is updated accordingly. The change follows assessment of the same change to the reference product, Bridion.   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000255111 | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/04/2025 | N/A |                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000261975   | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.b Addition of a new test(s) and limits - Accepted                                                                                                                                                         | 27/03/2025   | N/A        |                       |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|
| Variation type IB / EMA/VR/0000253871   | This was an application for a group of variations. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is | 12/03/2025   | 06/06/2025 | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

|                                       | responsible include batch release - Accepted C.I.2.a (IB) - To update section 4.8 of the SmPC to add information on hypersensitivity reactions for sugammadex-rocuronium complex, following approval of the same changes in the reference product. A.5.a (IAIN) - To change the name of the site responsible for quality control testing and batch release of the finished product from Eurofins Analytical Services Hungary Kft (Anonymus Utca 6, Kerulet, Budapest IV, 1045, Hungary) to Eurofins BioPharma Product Testing Budapest Kft. The address remains unchanged. Furthermore, the Marketing Authorisation Holder has taken the opportunity to remove the United Kingdom (Northern Ireland) from the list of   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000246130 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of                                                                                                                                                                                                                                                                                      | 10/03/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation - Accepted                                                                                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - B.I.d.1.z Other variation - Accepted |